A patient injects herself with an insulin pen.
Guido Krzikovsky | Bloomberg | Getty Images
Do you think a friend or colleague should receive this newsletter?share this link Sign up with them.
Competition between Good Afternoon! Eli Lilly and Company and Novo Nordisk Its scope goes beyond a popular class of weight-loss and diabetes drugs called GLP-1.
Two drugmakers are also racing to develop Weekly insulin injection.
These injections may provide a longer-lasting, more convenient option compared to daily insulin and other common diabetes treatments.
People with type 1 diabetes need insulin every day. Meanwhile, about one-third of people with type 2 diabetes require insulin injections to keep their blood sugar within a healthy range, according to some. estimate. But some people refuse or delay treatment due to reasons such as inconvenience and pain, which can worsen their long-term health.
Successful weekly shots for Eli Lilly and Novo Nordisk to maintain Dominant position in the insulin market. Eli Lilly, Novo Nordisk and French drugmaker Sanofi together control about 90% of the U.S. insulin market and have faced political pressure to make the life-sustaining drugs available. Diabetes treatments are getting cheaper.
The race to develop less frequent insulins heated up Thursday after Eli Lilly and Co. went public positive initial data From two late-stage clinical trials of weekly injections of efsitora in patients with type 2 diabetes. The company is also studying the experimental drug in people with type 1 diabetes.
Efsitora is Eli Lilly’s answer to Novo Nordisk’s experimental weekly insulin injection, codec.
TD Cowen analyst Steve Scala said in a note on Friday that new data from Eli Lilly and Co.’s efsitora looked “competitive” but “somewhat inferior” to Novo Nordisk’s icodec when compared in clinical trials. . He added that Eli Lilly’s shot lags one to two years behind Novo Nordisk’s shot.
Icodec recent respected for approval in Europe.The U.S. Food and Drug Administration advisory panel also Meeting on Friday Discuss Novo Nordisk’s U.S. approval application
An employee inspects insulin bottles at a factory of US pharmaceutical company Eli Lilly and Company in Figelsheim, eastern France.
Patrick Herzog | AFP | Getty Images
Let’s take a deeper look at Eli Lilly’s new data.
The pharmaceutical giant said that in two trials, efsitora was as effective as commonly used daily insulin injections in controlling blood sugar in adults with type 2 diabetes.
In a trial called QWINT-2, Eli Lilly is comparing its insulin to a daily injection called insulin degludec.Novo Nordisk sells this product under the brand name Trishba.
The patients in the trial were taking insulin for the first time, and some were also taking GLP-1 drugs.
At the end of 52 weeks, patients taking efsitora had a 1.34% reduction in A1C, a marker of blood sugar levels over three months, while insulin degludec had a 1.26% reduction. Eli Lilly added that its injection was as effective as daily insulin in lowering A1C levels, regardless of whether patients took GLP-1 in the study.
The second study, called QWINT-4, compared Eli Lilly’s efsitora to daily injections of insulin glargine. Eli Lilly, Sanofi and other drugmakers market the treatment under different brand names.
The trial looked at efsitora in a group of diabetic patients who had previously received multiple daily insulin injections. After 26 Weeks, Eli Lilly’s New Weekly injection and insulin glargine reduced A1C levels by 1.07%.
Eli Lilly said efsitora was “safe and well-tolerated” by patients in both studies. The company will present complete data from the QWINT-2 trial at the European Association for the Study of Diabetes annual meeting in September. Eli Lilly also expects to have preliminary results from three other late-stage studies later this year.
We’ll see what the data looks like.
Please feel free to send Annika any tips, suggestions, story ideas and data: annikakim.constantino@nbcuni.com.
Latest Healthcare Technology
Uber announces new features for caregivers
On August 20, 2020, the Uber logo appeared at Los Angeles International Airport in California.
Robin Baker | AFP | Getty Images
Uber A new feature was recently announced that makes it easier for users to support their loved ones.
Starting this summer, the feature, called “Uber Caregiver,” will allow individuals to add their caregivers directly to their profiles. By doing this, caregivers can book rides for the person they support and order medical supplies, meals and groceries on their behalf.
Swathi Bhat, head of product at Uber Health, said the company knows it’s not just doctors and nurses who provide care for others. In fact, she noted that nearly 25% of Americans consider themselves caregivers, according to the Centers for Disease Control and Prevention.
“Caring for an elderly loved one is often financially, emotionally and time-consuming. That’s why this summer, we launched Uber Caregiver,” Bart said at Uber’s annual Go-Get product showcase in New York City last week.
Uber Caregiver marks an expansion of Uber’s existing healthcare services. Bhat’s team helps health care providers and insurance companies arrange rides for patients and deliver prescriptions, groceries and other over-the-counter items through the Uber Health dashboard.
But by bringing many of these features directly to caregivers’ fingertips, Barth said it will be easier for everyday people to help coordinate care.
Uber defines a caregiver as any trustworthy person over the age of 18.
In addition, Uber said users’ insurance benefits can be used where applicable to help minimize out-of-pocket costs. Uber Caregiver will initially support Medicaid beneficiaries, customers 65 and older with Medicare Advantage, and users with employer commercial insurance.
Caregivers can sign up to be notified when other insurance providers gain support for this feature.
Please feel free to send Ashley any tips, suggestions, story ideas, and data: ashley.capoot@nbcuni.com.
About The Author
